Complicated Urinary Tract Infections Market Insight, Epidemiology And Market Forecast - 2036

Published Date : 2026
Pages : 242
Region : United States, Japan, EU4 & UK

Complicated Urinary Tract Infection Market Summary

  • The Complicated Urinary Tract Infections Therapeutics Market in the 7MM was valued at ~USD 1,375 million in 2025 and is projected to reach USD 2,259 million by 2036 over the forecast period from 2026 to 2036.
  • The Complicated Urinary Tract Infections Therapeutics Market is projected to grow at a CAGR of 5.7% by 2036 in leading countries (US, EU4, UK and Japan).

Complicated Urinary Tract Infections Market and Epidemiology Analysis

  • In 2024, there were approximately 8,266,000 diagnosed incident cases of Complicated Urinary Tract Infections in the 7MM.
  • In the 7MM, female accounted for approximately 70% cases and male accounted for almost 30% of cases of Complicated Urinary Tract Infections in 2024.
  • Treatment for Complicated Urinary Tract Infections typically lasts 7–14 days and often requires hospitalization with IV broad-spectrum antibiotics, especially in cases involving multidrug-resistant organisms or severe illness.
  • Empiric therapy may include extended-spectrum cephalosporins, beta-lactamase inhibitors, or carbapenems for high-risk patients. Newer agents like ceftazidime-avibactam and ceftolozane-tazobactam are effective against resistant gram-negative pathogens, including ESBL-producing and fluoroquinolone-resistant strains.
  • In 2024, the United States dominated the Complicated Urinary Tract Infections Therapeutics Market among the 7MM, capturing approximately 57% of the total 7MM market share.
  • In 2024, the Complicated Urinary Tract Infections Therapeutics Market Size in EU4 and the UK was approximately USD 454 million, accounting for almost 34% of market in 7MM.
  • The leading Complicated Urinary Tract Infections Companies include Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Melinta Therapeutics, Menarini Group, Meiji Seika Pharma, Fedora Pharmaceuticals, and others are developing therapies for Complicated Urinary Tract Infections treatment.
  • Wockhardt stated in its annual report that global approval for ZAYNICH was expected by the end of 2025 or early 2026.
  • Meanwhile, the pipeline for Complicated Urinary Tract Infections continues to expand, with drugs such as Tebipenem Pivoxil Hydrobromide (SPR994), (zidebactam/cefepime, WCK 5222), Cefepime/Taniborbactam (VNRX-5133) and others showing promise in clinical development.

Complicated Urinary Tract Infections Market Size and Forecast in the 7MM

2025 Complicated Urinary Tract Infections Market SizeUSD 1,375 million
2036 Projected Complicated Urinary Tract Infections Market SizeUSD 2,259 million
Complicated Urinary Tract Infections Growth Rate (2026-2036)5.7% CAGR
Largest Complicated Urinary Tract Infections MarketUnited States

Complicated Urinary Tract Infections Market Insight

DelveInsight's "Complicated Urinary Tract Infections Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of the Complicated Urinary Tract Infections, historical and forecasted epidemiology as well as the Complicated Urinary Tract Infections therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Scope of the Complicated Urinary Tract Infections Market Report

Study Period

2022 to 2036

Forecast Period

2026-2036

Geographies Covered 

  • The US, EU4 (Germany, France, Italy, and Spain), and the UK, Japan

Complicated Urinary Tract Infections Market

  • Total Market Size
  • Market Size by Therapies
  • Market Size by Class

Complicated Urinary Tract Infections Market Size

~USD 1,375 Million in 2025

Complicated Urinary Tract Infections Companies

  • Spero Therapeutics
  • Wockhardt
  • Venatorx Pharmaceuticals
  • Melinta Therapeutics
  • Menarini Group
  • Meiji Seika Pharma
  • Fedora Pharmaceuticals

Complicated Urinary Tract Infections Epidemiology Segmentation

  • Complicated Urinary Tract Infections Diagnosed Incident Cases
  • Complicated Urinary Tract Infections Age-specific Cases
  • Complicated Urinary Tract Infections Gender-specific Cases
  • Complicated Urinary Tract Infections Pathogen-specific Cases
  • Complicated Urinary Tract Infections Treated Cases

Key Factors Driving the Growth of the Complicated Urinary Tract Infection Market

In 2024, over 1 million diagnosed incident cases of Complicated Urinary Tract Infections progressed to Complicated Urinary Tract Infections in the 7MM, which is expected to increase during the forecast period (2026–2036).

  • Rising Catheter Use Driving Complicated Urinary Tract Infections Market Expansion

Rising use of urinary catheters and other drainage devices is likely to drive an uptick in Complicated Urinary Tract Infections treatment market growth, as patients using urinary catheters are more likely to acquire Complicated Urinary Tract Infections.

  • Expected Launch of Emerging Complicated Urinary Tract Infections Drugs

Some of the drugs in the pipeline include tebipenem pivoxil hydrobromide, cefepime/zidebactam, and cefepime-taniborbactam, among others.

Complicated Urinary Tract Infection Disease Understanding

Complicated Urinary Tract Infection Overview

UTIs are one of the most frequent infectious illnesses in the world, yet they remain understudied. Although uropathogenic E. coli (UPEC) accounts for a high percentage of UTIs, various bacteria, each of which will have its host–pathogen interactions with the bladder environment, can infect the urinary tract.

UTIs present in various forms, from mild uncomplicated cases to more serious conditions like Complicated Urinary Tract Infections, pyelonephritis, and urosepsis, making patient stratification essential. Complicated Urinary Tract Infections carry a higher risk of recurrence, chronicity, and severe outcomes, largely influenced by host factors rather than pathogens. These infections are also commonly associated with high rates of antibiotic resistance.

Asymptomatic Bacteriuria is the most common form of complicated urinary infection, especially prevalent in patients with chronic catheters, neurogenic bladder, or elderly residents in care facilities. Symptomatic cases range from mild urinary symptoms to severe conditions like bacteremia and sepsis, with complete obstruction or trauma—particularly with hematuria—linked to more serious outcomes.

Further details are provided in the report…

Complicated Urinary Tract Infection Diagnosis

This diagnosis of a complicated urinary tract infection is based on three main features: the clinical picture, microbiological tests, and radiological investigations. Clinical Picture: The most common clinical presentations of UTI include acute cystitis, pyelonephritis, and less commonly acute prostatitis, but patients with abnormal urinary tracts can present more atypically.

  • Laboratory Tests: Basic laboratory tests may reveal elevated inflammatory markers, and renal function should be recorded. The urine dipstick is a simple and cheap bedside test and is very useful in confirming a diagnosis of UTI.
  • Radiological Tests: All patients with complicated urinary tract infections, including first-time pyelonephritis in healthy nonpregnant women, should undergo renal ultrasound to assess for obstruction or abnormalities, as these cannot be reliably excluded by clinical evaluation alone.

Further details related to country-based variations are provided in the report…

Complicated Urinary Tract Infection Treatment

Treatment for complicated UTIs tends to take longer compared with simple UTIs, and may take between 7 and 14 days. While a course of antibiotics may treat a typical UTI at home, complicated cases may require broad-spectrum, intravenous antibiotics as well as hospitalization. The exact treatment timeline depends on how soon patient’s body responds to broad-spectrum antibiotics, as well as whether any complications develop.  

The treatment goals are to get rid of the infection, prevent complications, and help provide symptomatic relief. In order to lower the risk of developing pyelonephritis, early treatment is recommended. When considering empirical antimicrobial selection, it is critical to recognize antimicrobial resistance trends. The main course of treatment for individuals with lower UTIs is an oral medication with an empirically selected antibiotic that is effective against Gram-negative aerobic coliform bacteria, such as Escherichia coli.

Further details related to treatment and management are provided in the report…

Complicated Urinary Tract Infection Epidemiology Insights

The Complicated Urinary Tract Infections epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by diagnosed incident cases of Complicated Urinary Tract Infections, age-specific cases of Complicated Urinary Tract Infections, gender-specific cases of Complicated Urinary Tract Infections, pathogen-specific cases of Complicated Urinary Tract Infections, and treated cases of Complicated Urinary Tract Infections in the United States, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan from 2022 to 2036.

Key Findings from Complicated Urinary Tract Infections Epidemiological Analyses and Forecast

  • In 2024, the Complicated Urinary Tract Infection Diagnosed Incident Cases were approximately 3,558,000 in the US.
  • In 2024, the age-specific cases of Complicated Urinary Tract Infections were approximately  40,000, 268,000, 247,000, 511,500, 1,759,500 and 732,000 cases for 0-17 years, 18–44 years, 45–54 years, 55–64 years, 65–84 years and =85 years, respectively, in the US.
  • In the US, male accounted for approximately 30% cases and female accounted for ~70% cases of Complicated Urinary Tract Infections in 2024.
  • In 2024, the treated Cases of complicated urinary tract infections were approximately 10,746,500 in the 7MM, out of which ~ 8,266,500 were 1st line and ~ 2,480,000 were recurrent rate.

Complicated Urinary Tract Infection Epidemiology Segmentation

Complicated Urinary Tract Infection Market Recent Breakthroughs

  • In September, 2026 – Pattern Bioscience announced that the FDA had granted Breakthrough Device Designation to its Urine ID/AST Panel, a rapid diagnostic test designed to identify urinary pathogens and assess antimicrobial susceptibility. The technology may help clinicians identify appropriate antibiotics more quickly, addressing an important challenge in managing complicated UTIs.
  • In September 2026, Clinical Infectious Diseases published a randomized clinical trial evaluating oral fosfomycin as transition therapy versus continued intravenous beta-lactam treatment for complicated UTIs caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales. The research is relevant to treatment strategies intended to reduce reliance on prolonged intravenous antibiotic therapy.

Complicated Urinary Tract Infection Prevalence

Complicated Urinary Tract Infection Drug Analysis

The section dedicated to drugs in the Complicated Urinary Tract Infections Therapeutics Market Report provides an in-depth evaluation of late-stage Complicated Urinary Tract Infections pipeline drugs (Phase III and Phase II) related to Complicated Urinary Tract Infections. The drug chapters section provides valuable information on various aspects related to clinical trials of Complicated Urinary Tract Infections, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. 

Furthermore, it presents the most recent news updates and press releases on drugs targeting Complicated Urinary Tract Infections.

Complicated Urinary Tract Infections Marketed Therapies

  • EXBLIFEP (Cefepime/Enmetazobactam): Allecra Therapeutics

EXBLIFEP (cefepime/enmetazobactam), a novel intravenous antibiotic targeting MDR gram-negative bacteria particularly ESBL-producing strains. Approved by the FDA in February 2024 for Complicated Urinary Tract Infections. Despite demonstrating strong clinical efficacy, especially against resistant pathogens, the drug was unexpectedly withdrawn from the US market. In March 2024, the European Commission granted marketing authorisation for EXBLIFEP for the treatment of adult patients with Complicated Urinary Tract Infections, including pyelonephritis.

  • RECARBRIO (imipenem, cilastatin, and relebactam): Merck Sharp & Dohme

RECARBRIO is a combination of imipenem, a cell wall inhibitor; cilastatin, a renal dehydropeptidase inhibitor; and relebactam, a beta-lactamase inhibitor. The recommended dose is 1.25 g (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) for adult patients with creatinine clearance of 90 mL/min or greater.

In July 2019, the US FDA approved RECARBRIO (imipenem, cilastatin, and relebactam), an antibacterial drug product to treat adults with Complicated Urinary Tract Infections. In February 2020, the European medicines agency granted marketing authorization to RECARBRIO for the treatment of gram-negative bacteria. In July 2021, the Ministry of Health, Labour and Welfare (MHLW) approved RECARBRIO for the treatment of infections caused by RECARBRIO-sensitive Escherichia coli, Citrobacter spp, Klebsiella spp, Enterococcus spp, Serratia spp, Pseudomonas aeruginosa, and Acinetobacter spp.

Comparison of Complicated Urinary Tract Infections Marketed Therapies

Drug Name

Company

MoA

RoA

Molecule Type

Approval

RECARBRIO (imipenem, cilastatin, and relebactam)

Merck Sharp & Dohme

Cell wall inhibitor/ Renal dehydropeptidase inhibitor/ Beta-lactamase inhibitor

IV

Small molecule

US:2019

EU:2020

JP:2021

ZERBAXA  (ceftolozane/tazobactam)

Merck Sharp & Dohme

Cephalosporin antibacterial / Beta-lactamase inhibitors

IV

Small molecule

For adults

US: 2014

EU: 2015

JP: 2019

<18 years old:

US: 2022

AVYCAZ/ ZAVICEFTA (Ceftazidime – Avibactam)

AbbVie

Cell wall inhibitor/ Beta-lactamase inhibitors

IV

Small molecule

US: 2018

EU: 2020

JP: 2024

FETROJA (cefiderocol)

Shionogi

Cell wall inhibitors

IV

Antibacterial

US: 2019

EU: 2020

VABOMERE (Meropenem/vaborbactam)

Melinta Therapeutics

Cell wall inhibitor/ Beta-lactamase inhibitors

IV

Small molecule

US-2017

EU-2018

Emerging Complicated Urinary Tract Infections Therapies

  • Tebipenem Pivoxil Hydrobromide (SPR994): Spero Therapeutics

Tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994) is an oral antibiotic used for the treatment of Complicated Urinary Tract Infections and AP to help patients avoid hospitalizations and/or transition patients to home after IV therapy.

In March 2019, Spero Therapeutics announced the US FDA grant of FTD for SPR994 for the treatment of Complicated Urinary Tract Infections and AP. Tebipenem HBr has also been granted Qualified Infectious Disease Product (QIDP) designations for Complicated Urinary Tract Infections.

  • ZAYNICH (zidebactam/cefepime, WCK 5222): Wockhardt

ZAYNICH, a combination of zidebactam and cefepime, is Wockhardt’s novel proprietary antibiotic, targeted towards MDR gram-negative infections. ZAYNICH is a novel ß-lactam enhancer mechanism of action drug, which overcomes all the clinically important resistance mechanisms in gram-negative pathogens, including tough-to-treat Pseudomonas, Stenotrophomonas, Acinetobacter, and Klebsiella.

ZAYNICH has completed a multi-national Phase III study, which would support its registration/marketing authorization globally. In December 2015, the US FDA granted breakthrough QIDP drug discovery status to WCK-5222.

Comparison of Complicated Urinary Tract Infections Emerging Therapies

Drug Name

Company

Phase

RoA

Molecule Type

MoA

Tebipenem PIntravenousoxil Hydrobromide

Spero Therapeutics

III

Oral

Small molecule

Cell wall inhibitors

Cefepime-zidebactam

Wockhardt

III

IV

Small molecule

Cell wall inhibitor/ Beta-lactamase enhancer

Cefepime/ taniborbactam

Venatorx Pharmaceuticals

III

IV

Small molecule

Cell wall inhibitor/ Beta-lactamase inhibitors

Nacubactam (OP0595)

Meiji

III

IV

Small molecule

Beta-lactamase inhibitors

XNW4107

Evopoint Pharmaceuticals

III

IV

Small molecule

Beta-lactamase inhibitors

Complicated Urinary Tract Infections Market OutlookComplicated Urinary Tract Infection Market Outlook

The Complicated Urinary Tract Infections market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Complicated Urinary Tract Infections market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Complicated Urinary Tract Infections market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Complicated Urinary Tract Infections Therapeutics Market in 7MM is expected to change in the study period 2022-2036. During the forecast period (2026–2036), pipeline candidates such as Tebipenem PIntravenousoxil Hydrobromide, Cefepime-zidebactam, Cefepime/ taniborbactam, and others are expected to drive the rise in Complicated Urinary Tract Infections market size.

Key findings from Complicated Urinary Tract Infections Market Forecast

  • The Complicated Urinary Tract Infections Therapeutics Market in the 7MM was valued at ~USD 1,375 million in 2025 and is projected to reach USD 2,259 million by 2034 at a CAGR of 5.7% over the forecast period from 2026 to 2036.
  • In 2024, in the EU4 and the UK, Germany has the highest Complicated Urinary Tract Infections Treatment Market Size of ~USD 115 million.
  • In 2024, the Complicated Urinary Tract Infections Treatment Market Size in Japan was ~USD 120 million.
  • In a nutshell, many potential therapies are being investigated to manage Complicated Urinary Tract Infections. Even though it is too soon to comment on the above-mentioned promising candidate to enter the market during the forecast period (2026–2036), it is safe to assume that the future of this market is bright. Eventually, these drugs will create a significant difference in the landscape of Complicated Urinary Tract Infections in the coming years. The treatment space is expected to experience a significant positive shift in the coming years owing to the improvement in healthcare spending worldwide.

Key Findings

This section includes a glimpse of the Complicated Urinary Tract Infections therapeutics market in 7MM.

The United States Complicated Urinary Tract Infections Market Outlook

This section provides the total Complicated Urinary Tract Infections market size and market size by therapies in the United States.

EU-5 Countries Complicated Urinary Tract Infections Market Outlook

The total Complicated Urinary Tract Infections market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Complicated Urinary Tract Infections Market Outlook

The total Complicated Urinary Tract Infections market size and market size by therapies in Japan is also mentioned.

Further details are provided in the report…

Complicated Urinary Tract Infections Drugs Uptake

This section focuses on the uptake rate of potential Complicated Urinary Tract Infections drugs expected to be launched in the market during 2026–2036. The landscape of Complicated Urinary Tract Infections treatment has experienced a profound transformation with the uptake of novel drugs.

Further detailed analysis of emerging therapies drug uptake in the report…

Complicated Urinary Tract Infections Clinical Trials Activities 

The Complicated Urinary Tract Infections pipeline report provides insights into Complicated Urinary Tract Infections clinical trials Phase III, Phase II, and Phase I/II. It also analyzes key players involved in developing targeted therapeutics.

Complicated Urinary Tract Infections Pipeline Development Activities

The Complicated Urinary Tract Infections clinical trials analysis report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for Complicated Urinary Tract Infections emerging therapies.

Latest KOL Views on Complicated Urinary Tract Infections

To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

We have reached out to industry experts to gather insights on various aspects of Complicated Urinary Tract Infections, including the evolving treatment landscape, patients’ reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.

What KOLs are saying on Complicated Urinary Tract Infections Patient Trends?

Our team of analysts at Delveinsight connected with more than 10 KOLs across the 7MM. We contacted institutions such as the University of Munich, the University of Tokyo, UCLA Medical Centre, and University of Minnesota, etc., among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Complicated Urinary Tract Infections market, which will assist our clients in analyzing the overall epidemiology and market scenario.

We perform Qualitative and Complicated Urinary Tract Infections Therapeutics Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies for Complicated Urinary Tract Infections based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in trials for Complicated Urinary Tract Infections, one of the most important primary endpoints was achieving Test-of-Cure, micro Intent-to-treat population, etc. Based on these, the overall efficacy is evaluated.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Complicated Urinary Tract Infections Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed.

Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

Inpatient prospective payment system (IPPS) participating acute care hospitals will be eligible to receive an NTAP for RECARBRIO up to USD 3,532.78 per qualified case starting at the beginning of October 2020 when RECARBRIO is used to treat Complicated Urinary Tract Infections and cIAI.

This additional payment will be given in addition to the MS-DRG reimbursement for Medicare inpatient cases that qualify. The ICD-10-PCS codes are XW033U5 (Introduction of imipenem-cilastatin-relebactam anti-infective into a peripheral vein, percutaneous approach, new technology group 50 and XW043U5 (Introduction of imipenem-cilastatin-relebactam anti-infective into central vein, percutaneous approach, new technology group 5).

The Complicated Urinary Tract Infections Therapeutics Market Report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Complicated Urinary Tract Infections Market Report

  • The report covers a segment of key events, an executive summary, and a descriptive overview of Complicated Urinary Tract Infections, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
  • Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
  • Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
  • A detailed review of the Complicated Urinary Tract Infections market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Complicated Urinary Tract Infections market.

Complicated Urinary Tract Infection Market Report Insights

Complicated Urinary Tract Infection Market Report Key Strengths

  • 11-year Complicated Urinary Tract Infections Market Forecast
  • The 7MM Coverage
  • Complicated Urinary Tract Infections Epidemiology Segmentation
  • Key Cross Competition
  • Complicated Urinary Tract Infections Drugs Uptake

Complicated Urinary Tract Infection Market Report Assessment

  • Current Complicated Urinary Tract Infections Treatment Practices
  • Complicated Urinary Tract Infections Market Reimbursements
  • Complicated Urinary Tract Infections Market Attractiveness
  • Qualitative Analysis (SWOT, Conjoint Analysis, Unmet Needs)
  • Complicated Urinary Tract Infections Market Drivers
  • Complicated Urinary Tract Infections Market Barriers

Key Questions Answered In The Complicated Urinary Tract Infections Market Report

  • Would there be any changes observed in the current treatment approach?
  • Will there be any improvements in Complicated Urinary Tract Infections management recommendations?
  • Would research and development advances pave the way for future tests and therapies for Complicated Urinary Tract Infections?
  • Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of Complicated Urinary Tract Infections?
  • What kind of uptake will the new therapies witness in the coming years in patients with complicated urinary tract infections?

Stay updated with us for Recent Articles

Frequently Asked Questions

A Complicated Urinary Tract Infection (cUTI) is a UTI that occurs in individuals with structural or functional abnormalities of the urinary tract, or with comorbidities, making it harder to treat and more likely to cause severe outcomes.
The Complicated Urinary Tract Infection Market Size in the 7MM is going to be ~USD 1375 Million in 2025, and expected to grow with a CAGR of 5.7% during the forecast period (2025-2034)
Among the 7MM, the United States accounted for the largest Complicated Urinary Tract Infection Market Size, i.e., approximately 57% of the overall Complicated Urinary Tract Infection Market in 2023.
The leading Complicated Urinary Tract Infection Companies developing potential therapies include Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Melinta Therapeutics, Menarini Group, Meiji Seika Pharma, Fedora Pharmaceuticals, and others
Key strengths of the Complicated Urinary Tract Infection Market Report are 10 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers, and Market Barriers, along with the upcoming market trends in the Complicated Urinary Tract Infection Market.
The United States is anticipated to have the highest prevalence of Complicated Urinary Tract Infection Cases.
The disease epidemiology covered in the Complicated Urinary Tract Infection Market report provides historical as well as forecasted epidemiology segmented by diagnosed incident cases of cUTI, age-specific cases of cUTI, gender-specific cases of cUTI, pathogen-specific cases of cUTI, and treated cases of cUTI in the 7MM.

Tags:

  • Complicated Urinary Tract Infections market
  • Complicated Urinary Tract Infections market research
  • Complicated Urinary Tract Infections market insight
  • Complicated Urinary Tract Infections market trends

Related Reports

report image delveinsight

Uncomplicated Urinary Tract Infections - Pipeline Insight, 2026

report image delveinsight

Complicated Urinary Tract Infections - Pipeline Insight, 2026

report image delveinsight

Complicated Urinary Tract Infections - Epidemiology Forecast - 2034

report image delveinsight

Uncomplicated Urinary Tract Infections Patient Pool Analysis, Market Size and Market Forecast APAC - 2036

Infographics

License Type


Offer

Request Sample

View Pricing

Customize Reports As Per Your Needs

Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

Have a Question?

We are happy to assist you.

Download Now

Infographic Image
DelveInsight
DelveInsight
SUBSCRIPTION
Platform

Register for free trial today and gain instant access to 7000+ market
research reports